Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) EPS (Weighted Average and Diluted) (2020 - 2025)

Oncology Institute (TOI) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.14 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 22.22% year-over-year to -$0.14, compared with a TTM value of -$0.64 through Sep 2025, up 17.95%, and an annual FY2024 reading of -$0.71, up 22.83% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.14 for Q3 2025 at Oncology Institute, roughly flat from -$0.14 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.21 in Q1 2022 and bottomed at -$0.33 in Q1 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.13, with a median of -$0.17 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 221691361.25% in 2021, then skyrocketed 1150.0% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.15 in 2021, then decreased by 20.0% to -$0.18 in 2022, then dropped by 16.67% to -$0.21 in 2023, then increased by 28.57% to -$0.15 in 2024, then rose by 6.67% to -$0.14 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TOI at -$0.14 in Q3 2025, -$0.14 in Q2 2025, and -$0.21 in Q1 2025.